France
Ciloa SAS, founded in 2011 and headquartered in France, positions itself at the forefront of the biotech industry with its slogan, "Inspired by Exosomes." Specializing in exosome-based research and development, the company focuses on creating innovative therapeutics that address traditionally undruggable targets.
Their proprietary technology customizes in vivo exosomes, embedding fully native membrane protein complexes and delivering specific cargo proteins, making it possible to develop virus-free therapeutic vectors. This approach also facilitates the development of antibodies against challenging membrane protein complex targets and virus-free candidate vaccines.
Ciloa's unique offerings in both therapeutics and preventive solutions are delivered through licensing and strategic partnerships. Their most recent venture round attracted a significant investment of €5.00M on 08 March 2022, underscoring investor confidence in the company's cutting-edge approaches in the health and wellness sector.
